Research brief / about this project
About Meds Sermorelin
A signal-first reading of the published GHRH(1-29) record — what it is, and what it is not.
What this site is
Meds Sermorelin publishes summaries of the peer-reviewed research literature on sermorelin (GHRH(1-29)). No clinician is on staff; no one here is advised or treated; nothing is manufactured, stocked, or sold. What the site produces is a sourced reading, organized so each finding sits beside the study that produced it — a record, not a service.
What the name means
The word 'meds' in this domain is editorial framing, not a service. This site does not dispense, prescribe, compound, or sell anything, and it is not a pharmacy or a storefront. The name signals the subject — a compound with a real clinical and regulatory history — and the register in which we cover it: a dark, release-note readout of the literature, where the status of the science is stated plainly and dated to its source. Sermorelin's own status is a case in point: a formerly FDA-approved compound, withdrawn for commercial reasons, now compounded — a status often misreported, which is exactly why we state it carefully.
How we handle the evidence
The editorial discipline here is simple: lead with what was measured, attribute it to the study, and mark the gaps as gaps. Where the data is precise — a ~10-12 minute half-life, a 117% IGF-1 rise in a controlled trial — we are precise. Where it is thin — long-term adult anti-aging safety — we say so rather than fill the space. Every quantitative claim on the site resolves to a numbered citation on the references page, and the tolerability caveats are surfaced as their own signal, never buried.
Why a sermorelin-specific reading is worth doing
Sermorelin sits in an awkward gap online: it has a genuine clinical and regulatory history, a characterized mechanism, and real trial data — and it is also wrapped in a layer of anti-aging promotion that frequently misstates both the science and the regulatory status. A focused reading can do one useful thing the noise can't: hold the actual record in one place, with each claim next to its source, the misreported approval history stated correctly, and the honest gaps left visible. That is the whole editorial premise here — the literature, read straight, in a register that flags what it doesn't know.
What we don't do
This site recommends no doses for humans, sells or sources no compound, and offers no treatment, consultation, or prescriptions. Research findings are described in study-attributed terms. Sermorelin is widely marketed for benefits that outrun the evidence; the role here is the opposite of that marketing — to report the record as it stands, including where it runs out.